Mesa Laboratories, Inc.

Equities

MLAB

US59064R1095

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 02:26:49 2024-04-29 pm EDT			5-day change	1st Jan Change
106.8 ^USD	+3.45%		+3.82%	+1.34%

Apr. 08	Mesa Laboratories, Inc. Amends and Restates Its Senior Secured Credit Agreement with Syndicate of Banks Led by JPMorgan Chase Bank, N.A	CI
Apr. 05	Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024	CI

Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding

April 04, 2024

Mesa Laboratories, Inc. announced that it has entered into separate, privately negotiated purchase agreements with a limited number of holders of its outstanding 2025 Notes at the gross proceeds of $71,250,000 on April 5, 2024. The principal amount of the transaction is $75,000,000. The notes bear 1.375% Convertible Notes due 2025.

Latest news about Mesa Laboratories, Inc.

Mesa Laboratories, Inc. Amends and Restates Its Senior Secured Credit Agreement with Syndicate of Banks Led by JPMorgan Chase Bank, N.A	Apr. 08	CI
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024	Apr. 04	CI
Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding	Apr. 04	CI
Mesa Laboratories, Inc. Provides Impairment Guidance for the Fourth Quarter of 2024	Apr. 02	CI
Earnings Flash (MLAB) MESA LABORATORIES Posts Q3 Revenue $53.5M	Feb. 05	MT
Earnings Flash (MLAB) MESA LABORATORIES Reports Q3 EPS $2.02	Feb. 05	MT
Mesa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors	Jan. 08	CI
Mesa Laboratories Maintains Quarterly Dividend at $0.16 a Share, Payable March 15 to Shareholders of Record as of Feb. 29	Jan. 04	MT
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024	Jan. 04	CI
Evercore ISI Upgrades Mesa Laboratories to Outperform From In-Line, Raises Price Target to $125 From $100	Jan. 04	MT
Mesa Laboratories Completes Acquisition of GKE's Chinese Sales Entity	Jan. 03	MT
Mesa Laboratories, Inc. acquired Beijing GKE Science & Technology Co. LTD for ?5 million	Dec. 30	CI
Earnings Flash (MLAB) MESA LABORATORIES Posts Q2 Revenue $53.2M	Nov. 06	MT
Earnings Flash (MLAB) MESA LABORATORIES Posts Q2 EPS $1.91	Nov. 06	MT
Tranche Update on Mesa Laboratories, Inc.'s Equity Buyback Plan announced on November 10, 2005.	Nov. 06	CI
Mesa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 06	CI
Mesa Laboratories Completes Acquisition of GKE's Sterilization Indicators Business, Testing Lab SAL	23-10-16	MT
Mesa Laboratories, Inc. entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for ?5 million.	23-10-15	CI
Mesa Laboratories, Inc. acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for ?80 million.	23-10-15	CI
Mesa Laboratories, Inc. Amends Four-Year Senior Secured Credit Agreement	23-10-10	CI
Mesa Laboratories Keeps Quarterly Dividend at $0.16 a Share, Payable Dec. 15 to Shareholders of Record as of Nov. 30	23-10-03	MT
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023	23-10-03	CI
Mesa Laboratories Inc Insider Sold Shares Worth $492,890, According to a Recent SEC Filing	23-09-19	MT
Mesa Laboratories Insider Sold Shares Worth $369,965, According to a Recent SEC Filing	23-09-14	MT

Chart Mesa Laboratories, Inc.

Duration

Period

More charts

Company Profile

Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-24 - Q4 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Mesa Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

103.2 USD

Average target price

130 USD

Spread / Average Target

+25.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
MESA LABORATORIES, INC.	+1.34%	557M
ABBOTT LABORATORIES	-2.79%	187B
MEDTRONIC PLC	-1.97%	106B
BECTON, DICKINSON AND COMPANY	-4.48%	66.9B
DEXCOM, INC.	+0.65%	49.45B
CENCORA, INC.	+16.56%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.61%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+0.91%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution